Table 2

SF-36 scale scores and adjusted mean differences between the overall CML population and the matched control group

SF-36 scalesCML patients, mean (SD)Matched control group, mean (SD)Mean difference* (95% CI)P
Physical health
    Physical functioning76.8 (24.8)80.5 (25.4)−3.9 (−6.7; −1.1).006
    Role physical61.6 (42.2)73.0 (40.2)−11.5 (−16.8; −6.3)< .001
    Bodily pain70.4 (26.2)70.7 (28.7)−0.3 (−3.7; 3.2).882
    General health52.7 (22.6)61.2 (22.9)−8.9 (−11.7; −6.0)< .001
    PCS46.0 (9.6)48.2 (10.3)−2.4 (−3.6; −1.3)< .001§
Mental health
    Vitality56.2 (21.2)60.7 (20.8)−4.6 (−7.4; −1.8).001
    Social functioning73.9 (22.7)76.7 (24.3)−2.9 (−6.0; 0.2).069
    Role emotional64.5 (40.7)73.9 (38.0)−9.6 (−14.9; −4.3)< .001
    Mental health67.1 (19.8)66.3 (21.7)0.6 (−2.1; 3.4).659
    MCS49.3 (9.8)50.2 (9.7)−0.9 (−2.3; 0.4).166
  • CML indicates chronic myeloid leukemia; PCS, physical component summary; MCS, mental component summary; SD, standard deviation; and CI, confidence interval.

  • * Mean differences adjusted for age, sex, education, geographical area, and marital status.

  • Exceeds minimally important difference (ie, 8 points for the SF-36 scales and 2 points for the PCS and MCS scores).

  • Statistically significant after Bonferroni adjustment (adjusted alpha = 0.05/8 = 0.006 25).

  • § Statistically significant (alpha = 0.05).